Could a tiny dose of IL-2 calm Crohn's flare-ups?

NCT ID NCT04263831

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a low dose of Interleukin-2 (IL-2) can safely reduce symptoms in people with moderate-to-severe Crohn's disease. About 30 participants aged 12 to 80 will receive the drug to find the best dose that works with the fewest side effects. The goal is to improve quality of life by easing Crohn's symptoms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Boston Children's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Mount Sinai

    RECRUITING

    New York, New York, 10029, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••